Day: December 2, 2021

Conference Call and Webcast Scheduled for December 15, 2021, 4:30 pm ET NEW YORK, NY, Dec. 02, 2021 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report first quarter 2022 financial results on Wednesday, December 15, 2021, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 pm Eastern Time. Wednesday, December 15th  @ 4:30 pm ETDomestic:                    877-407-0792International:               201-689-8263Conference ID:             13725234Webcast:                      Registration Link — Click Here About Enzo Biochem Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development...

Net Sales Increased 6.8% to $289.5 MillionDiluted Earnings Per Share Increased 7.8% to $1.25 LYNNWOOD, Wash., Dec. 02, 2021 (GLOBE NEWSWIRE) — Zumiez Inc. (NASDAQ: ZUMZ) a leading specialty retailer of apparel, footwear, equipment and accessories for young men and women, today reported results for the third quarter ended October 30, 2021. Net sales for the third quarter ended October 30, 2021 (13 weeks) increased 6.8% to $289.5 million from $271.0 million in the third quarter ended October 31, 2020 (13 weeks). Compared to the third quarter ended November 2, 2019 (13 weeks), third quarter 2021 net sales increased 9.6%. Net income in the third quarter of fiscal 2021 was $30.7 million, or $1.25 per diluted share, compared to net income of $29.1 million, or $1.16 per diluted share, in the third quarter of the prior fiscal year. Net...

Company Announces Additional $200M Share Repurchase Authorization HARRISBURG, Pa., Dec. 02, 2021 (GLOBE NEWSWIRE) — Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) today reported financial results for the third quarter ended October 30, 2021. Third Quarter Summary:Total net sales decreased 7.5% to $383.5 million. Comparable store sales decreased 15.5% from the prior year increase of 15.3%. Comparable store sales decreased 1.3% compared with the third quarter of fiscal 2019. The Company opened 18 new stores, ending the quarter with 426 stores in 29 states, a year-over-year increase in store count of 10.6%. Operating income decreased 47.7% to $30.2 million and operating margin decreased 600 basis points to 7.9%. Adjusted operating income(1) decreased 48.3% to $29.9 million and adjusted operating margin(1)...

Entered into $31.25 million Private Placement Agreement Completed Initial Public Offering of Common Stock and Raised $28.75 million in Gross Proceeds Dosed First Patient in Phase 2 ER+, PR+, HER2- Metastatic Breast Cancer Clinical Trial PHILADELPHIA, Dec. 02, 2021 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers, today announced financial results for the third quarter ended September 30, 2021, and highlighted recent corporate accomplishments. “This is a pivotal time for Context, as we debuted on Nasdaq and entered into a $31.25 million private placement agreement that extends our cash runway into 2024. We also strengthened our leadership team with the addition of Chief Financial Officer...